Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.

The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-α2a/RBV therapies on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of treatment.Plasma HCV viral decline was analyzed between baseline and weeks 1, 2 and 4 in two groups of...

Full description

Bibliographic Details
Main Authors:	Antonio Rivero-Juárez, Luis F Lopez-Cortes, Angela Camacho, Almudena Torres-Cornejo, Juan A Pineda, Manuel Marquez-Solero, Antonio Caruz, Rosa Ruiz-Valderas, Julian Torre-Cisneros, Alicia Gutierrez-Valencia, Antonio Rivero
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3493612?pdf=render

Similar Items

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
by: Juan Macías, et al.
Published: (2015-01-01)

HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
by: Antonio Rivero-Juarez, et al.
Published: (2014-01-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients.
by: Antonio Rivero-Juarez, et al.
Published: (2013-01-01)

Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
by: Iwona Bukowska-Ośko, et al.
Published: (2015-01-01)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
Published: (2009-06-01)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
by: Kamil Grubczak, et al.
Published: (2021-07-01)

Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin
by: Karamitros, T, et al.
Published: (2011)

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
by: Vogel M, et al.
Published: (2010-03-01)

Conventional Versus Pegylated Interferons in Treatment of HCV Patients
by: M Amirbigi, et al.
Published: (2012-04-01)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
by: Helen Kovari, et al.
Published: (2015-01-01)

Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman
by: Hamid Hasson, et al.
Published: (2014-12-01)

Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2
by: O O Znoyko, et al.
Published: (2016-05-01)

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study
by: M. Laguno, et al.
Published: (2016-12-01)

Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
by: Giulia Marchetti, et al.
Published: (2012-01-01)

A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV
by: Maribel Rodriguez-Torres, et al.
Published: (2014-07-01)

IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
by: Emilie Estrabaud, et al.
Published: (2015-01-01)

Severe psoriasis emerged after treatment of chronic HCV co-infection with pegylated-interferon and ribavirin, supported by neutropenia rescue with repeated filgrastim administration
by: Sabbatani Sergio, et al.
Published: (2010-05-01)

Pegylated interferon, ribavirin, and frequent supportive therapy with growth factors. Which pathogenesis for a severe psoriasis complicating the treatment of chronic HCV hepatitis?
by: Roberto Manfredi
Published: (2009-12-01)

Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
by: Montserrat de Castellarnau, et al.
Published: (2012-01-01)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
by: Chen Z, et al.
Published: (2017-08-01)

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.
by: Claus Niederau, et al.
Published: (2014-01-01)

Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
by: Sara Corchado, et al.
Published: (2014-01-01)

Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis
by: Amira Youssef Shaala, et al.
Published: (2015-09-01)

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.
by: Ester Aparicio, et al.
Published: (2010-10-01)

PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study
by: Javier Milara, et al.
Published: (2015-01-01)

Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment
by: Kainuma Mosaburo, et al.
Published: (2010-04-01)

Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin
by: Fabio Conti, et al.
Published: (2014-03-01)

Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment
Published: (2007-06-01)

Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - Case report
by: Gliga Smaranda, et al.
Published: (2011-03-01)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
by: Amit Chopra, et al.
Published: (2015-01-01)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
Published: (2013-09-01)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
by: Roberto J Carvalho-Filho, et al.
Published: (2010-03-01)

Presence of HCV RNA in peripheral blood mononuclear cells may predict patients' response to interferon and ribavirin therapy
by: Nasib Zaman, et al.
Published: (2014-09-01)

Induction with ribavirin in a relapsing patient with chronic HCV hepatitis
by: Claudio Ucciferri, et al.
Published: (2012-05-01)

Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done?
by: Donald M. Jensen
Published: (2009-01-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia
by: Kokanov Nikola S., et al.
Published: (2023-01-01)

Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.
by: Antonio Rivero-Juárez, et al.
Published: (2013-01-01)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
by: Gonçales Neiva SL, et al.
Published: (2010-07-01)